JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2006; 48:12-14, doi:10.1016/j.jacc.2006.04.017 (Published online 7 June 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2006.04.017v1
48/1/12    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haga, S. B.
Right arrow Articles by Ginsburg, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haga, S. B.
Right arrow Articles by Ginsburg, G. S.

VIEWPOINT

Prescribing BiDil

Is It Black and White?

Susanne B. Haga, PhD* and Geoffrey S. Ginsburg, MD, PhD

Center for Genomic Medicine, Institute for Genome Sciences & Policy, Duke University, Durham, North Carolina.

Manuscript received February 21, 2006; accepted February 21, 2006.

* Reprint requests and correspondence: Dr. Susanne B. Haga, Senior Policy Scientist, Institute for Genome Sciences & Policy, Duke University, 101 Science Drive, Box 3382, Durham, North Carolina 27708. (Email: susanne.haga{at}duke.edu).

The approval of BiDil as an adjunct treatment in self-identified blacks with heart failure raises questions regarding the underlying etiology of drug response in this target population and the ability to accurately identify patients who are most likely to benefit. Preliminary data have indicated that differences in nitric oxide synthesis between groups may account for differences in response to BiDil and genetic studies have begun to elucidate the mechanism of these differences. Until more accurate selection criteria are developed to identify patients who are most likely to benefit, both clinicians and the general public will need to consider the unique issues raised by BiDil.

Abbreviations and Acronyms
  ACE = angiotensin-converting enzyme
  FDA = Food and Drug Administration
  HF = heart failure




This article has been cited by other articles:


Home page
 DOC NewsHome page
S. Kreimer
BiDil Not Widely Prescribed
DOC News, July 1, 2007; 4(7): 23 - 23.
[Full Text]

Home page
 ANN INTERN MEDHome page
R. Temple and N. L. Stockbridge
BiDil for Heart Failure in Black Patients: The U.S. Food and Drug Administration Perspective
Ann Intern Med, January 2, 2007; 146(1): 57 - 62.
[Abstract] [Full Text] [PDF]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.